Pancreatic cancer (PC) continues to demand urgent therapeutic innovation given its limited treatment options. Here, through phenotypic screening of a natural product library followed by systematic validation, we identified chrysosplenetin (CHR) as a bioactive compound with anti-PC activity. Transcriptomic profiling and...
In pancreatic ductal adenocarcinoma (PDAC), the desmoplastic stroma and immunosuppressive tumor microenvironment (TME) present barriers to immunotherapy. Here, we show that MG53 (TRIM72) is a critical regulator of macrophage fate and anti-tumor immunity; its myeloid-specific depletion accelerates PDAC progression by lo...
Yu-Meng Pei, Meng Fang, Fan Zhang et al.· Cell Reports· 0 citations
Hepatocellular carcinoma (HCC) management is challenging due to its complex tumor microenvironment and poor treatment responses. Here, using tumor specimens from a prospective clinical trial of combined transarterial chemoembolization (TACE) with immune checkpoint blockade (ICB), we perform exhaustive multi-omics analy...
Jian-Peng Sheng, Jin-Yuan Song, Lin Wang et al.· Cell Reports Medicine· 0 citations
Findings indicated a tumor-suppressing role of PBRM1 in PDAC, which constitutes a specific subgroup of patients with aggressive phenotype and prognostic significance.
Jin Li, Risheng Que, Jian Zhang et al.· Cancer Letters· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
